Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi IV: Nutrition Therapy and Prevention01:27

Urinary Tract Calculi IV: Nutrition Therapy and Prevention

Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.

Alimentary pharmacology & therapeutics·2026
Same author

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026
Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026
Same author

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Alimentary pharmacology & therapeutics·2026
Same author

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Alimentary pharmacology & therapeutics·2026

Related Experiment Video

Updated: May 15, 2026

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis
06:14

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Published on: January 12, 2024

New therapies for gout.

Daria B Crittenden1, Michael H Pillinger

  • 1Crystal Diseases Study Group, Division of Rheumatology, Department of Medicine, NYU School of Medicine/NYU Langone Medical Center, New York, New York 10003, USA. daria.crittenden@nyumc.org

Annual Review of Medicine
|January 19, 2013
PubMed
Summary

Gout management is improving with new therapies targeting inflammation and urate levels. Recent advances include FDA-approved colchicine, IL-1β inhibitors, and novel urate-lowering drugs, alongside lifestyle changes.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Biochemistry

Background:

  • Gout prevalence is rising, with current treatments often insufficient.
  • Understanding gout's underlying biology reveals new therapeutic targets.

Purpose of the Study:

  • To review novel and emerging strategies for managing gout, focusing on inflammation and urate reduction.
  • To highlight recent advancements in pharmacotherapy and lifestyle interventions for gout.

Main Methods:

  • Review of recent scientific literature and clinical trial data on gout therapeutics.
  • Analysis of new drug mechanisms targeting interleukin-1 beta (IL-1β), urate synthesis, excretion, and catabolism.

Main Results:

  • Colchicine has received FDA approval with a safer dosing regimen.

Related Experiment Videos

Last Updated: May 15, 2026

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis
06:14

Tuina Intervention in Sodium Monoiodoacetate Injection-Induced Rat Model of Knee Osteoarthritis

Published on: January 12, 2024

  • Interleukin-1 beta (IL-1β) inhibitors (e.g., canakinumab, rilonacept, anakinra) show promise for acute gouty inflammation.
  • Novel urate-lowering agents include synthesis inhibitors (febuxostat, BCX4208), URAT-1 inhibitors (lesinurad), and recombinant uricase (pegloticase).

    • Conclusions:

    • Emerging therapies offer improved efficacy for gout inflammation and urate lowering.
    • These novel treatments complement, rather than replace, essential lifestyle and dietary modifications.
    • Continued research in gout biology is driving significant clinical progress.